NIH stopped Study of Niacin
On Thursday the National Institutes of Health (NIH) halted a major research of high-dose niacin, a kind of B vitamin, over a yr forward of schedule as a consequence of the lack of advantage. It was the newest setback inside the quest to harness great cholesterol to combat the negative kind.
The trial, sponsored by the U.S. National Institutes of Health plus a drug maker, enrolled patients that has a historical past of heart disease who had their “bad” LDL cholesterol below management with statin drugs. The new trial hoped to work with niacin (also referred to as vitamin B3) to enhance ranges of “good” HDL cholesterol whilst reducing blood levels of fats called triglycerides to assist reduce the odds of heart attack or stroke.
The latest research tested Abbott Laboratories’ Niaspan, an extended-release type of niacin that is a far higher dose than is found in dietary supplements. The drug has long been sold for a long time, and earlier research have proven it does improve HDL levels.
Read more detail at:
